Loading stock data…
Relay Therapeutics, Inc. (RLAY)
$19.74+1.18 (+6.36%)
Market ClosedLast close Jun 29
Relay Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Relay Therapeutics, Inc. in the Healthcare sector is trading at $19.74 with a market capitalization of $3.3B. Wall Street consensus targets $24.82 (11 analysts), implying a +25.7% move over the next 12 months. The stock is currently near its 52-week high of $19.93, remaining 102.9% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +25.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.00M↓ | $7.00M | $0↓ | $677,000↓ | $7.68M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$78.59M↓ | -$60.63M↑ | -$80.39M↓ | -$76.85M↑ | -$84.87M |
| Net Income | -$73.29M↓ | -$54.89M↑ | -$74.15M↓ | -$70.38M↑ | -$77.06M |
Peer Comparison
JNJUNHPFE
Fundamentals
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The compa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.33B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.75
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-42.47%
Volume
Today's trading volume
4.11M
Recent News
Relay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past Year
This precision oncology innovator, up nearly 500% in a year, just reported significant insider selling amid ongoing drug development efforts.
Relay Therapeutics (RLAY) is One of the Best AI Driven Biotech Stocks, Here is Why
Relay Therapeutics Inc. (NASDAQ:RLAY) is one of the 10 best AI driven biotech stocks to invest in. On May 20, JonesResearch updated its coverage on Relay Therapeutics Inc. (NASDAQ:RLAY) after reviewing encouraging initial data for its drug, zovegalisib. The firm upgraded its rating on the stock from a Hold to a Buy. The firm also […]
Is Relay Therapeutics a Buy After Promising Trial Results?
Relay Therapeutics, a clinical-stage biotech, is getting a boost after positive trial news for its lead therapy.
Relay Therapeutics (RLAY) Is Up 6.9% After Follow-On Offering And Early Zovegalisib Data Release
Earlier this week, Relay Therapeutics completed a US$275,000,004 follow-on equity offering at US$12.00 per share, shortly after reporting initial Phase 2 ReInspire data showing that zovegalisib led to a 60% volumetric response rate and broad symptom improvement in patients with PIK3CA-driven vascular anomalies. The results, which highlighted lesion shrinkage in most patients and a safety profile considered suitable for chronic use, underscore Relay’s bid to position zovegalisib as a...
Why Relay Therapeutics Stock Popped on Wednesday
In a way, this was a delayed reaction to excellent news from the lab.